A number of affected person traits — spleen measurement, symptom burden and blood counts, amongst others — are considered when deciding upon the most effective JAK inhibitor to deal with myelofibrosis, a kind of myeloproliferative neoplasm (MPN).
Dr. Prithviraj Bose, professor within the division of leukemia at The College of Texas MD Anderson Most cancers Heart in Houston, spoke with CURE onsite on the Society of Hematologic Oncology 2024 Annual Assembly, to debate these components to doubtlessly optimize collection of the accessible JAK inhibitors for sufferers with myelofibrosis.
Transcript:
There’s numerous completely different affected person traits one appears at. So, one appears on the measurement of the spleen, one appears on the burden of signs, and one appears on the blood counts. So, this can be a distinctive most cancers the place remedy will not be by … stage of the most cancers, or, it is not very algorithmic when it comes to what’s entrance line, what’s second line, what’s third line. So it is actually based mostly on the necessity of the affected person.
Now, once more, usually, I’ll say of the 4 [Food and Drug Administration-]accredited JAK inhibitors — once more, JAK inhibitors are all we’ve accredited in myelofibrosis — I feel ruxolitinib (Jakafi), fedratinib (Inrebic), pacritinib (Vonjo) and momelotinib (Ojjaara), can all be utilized in frontline [setting], however I feel what actually occurs is that it is both ruxolitinib or momelotinib, with momelotinib being favored if the affected person is anemic, and in any other case ruxolitinib. I’ll say the bulk [of patients] get ruxolitinib as a result of it’s so good for spleen and signs, and it has a survival profit that is been proven [in clinical data].
Within the second line, I feel it goes again extra to what I used to be saying concerning the scientific presentation. You probably have good counts, massive spleen, by all means, go along with fedratinib. You probably have, anemia, predominant presentation the place that is what you are attempting to enhance essentially the most, momelotinib, I feel, is your best option. If the platelets are tremendous low, which is uncommon to occur in [the] entrance line [setting], rather more widespread in second and later traces, if it lower than 50 [platelets per microliter of blood], completely pacritinib. That has the most effective information, and it has good efficacy there. So I feel … you can not set actual guidelines, however these are just a few pointers.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
